Canary Submits Site Evidence Package to Health Canada Pursuant to Cannabis License Application
Retrieved on:
Tuesday, May 14, 2019
NORFOLK COUNTY, ON, May 14, 2019 /PRNewswire/ -Target Group Inc. (OTCQB: CBDY) is pleased to announce that itswholly owned subsidiary, Canary Rx Inc. ("Canary" or the "Company") has submitted a Site Evidence Package to Health Canada pursuant to its Cultivation, Processing and Sales License application under the Cannabis Act.
Key Points:
- NORFOLK COUNTY, ON, May 14, 2019 /PRNewswire/ -Target Group Inc. (OTCQB: CBDY) is pleased to announce that itswholly owned subsidiary, Canary Rx Inc. ("Canary" or the "Company") has submitted a Site Evidence Package to Health Canada pursuant to its Cultivation, Processing and Sales License application under the Cannabis Act.
- The Site Evidence Package demonstrates to Health Canada that Canary's facility is complete, compliant and operationally ready.
- Completion of the Site Evidence Package represents a significant development towards Canary's ambition to produce small-batch, premium, organic cannabis.
- "The Canary team is delighted to have accomplished the final step in our application process", said Randall McLeod, CEO and President of Canary.